Emerging drugs for psoriatic arthritis

Expert Opinion on Emerging Drugs
Francesco CasoLuisa Costa

Abstract

The majority of Psoriatic Arthritis patients experience a good clinical response to anti-Tumor Necrosis Factor (TNF)-α therapies. However, treatment failure with anti-TNF-α can represent a relevant clinical problem. We review the efficacy and safety profile of biological therapies that have been reported from randomized, controlled trials in phase II and phase III available in Pubmed Database for agents targeting IL-12/23p40 antibody (ustekinumab) and IL-17 (secukinumab), inhibitor of phosphodiesterase 4, (apremilast), and of JAK/STAT pathways (tofacitinib) and CTLA4 co-stimulation (abatacept) in Psoriatic Arthritis. In Psoriatic Arthritis, main emerging drugs are represented by the fully human monoclonal IL-12/23p40 antibody, ustekinumab, the agent targeting IL-17, secukinumab, and the inhibitor of phosphodiesterase 4, apremilast. Results on T cell co-stimulation inhibition by abatacept are insufficient both in psoriasis and in PsA. In vitro investigations on JAK/STAT pathways in PsA suggest that tofacitinib could represent a further valuable therapeutic option. Emerging biological treatments other than anti-TNF agents, ustekinumab, secukinumab and apremilast appear promising for Psoriatic Arthritis and recent studies have sho...Continue Reading

References

Jan 1, 1973·Seminars in Arthritis and Rheumatism·J M Moll, V Wright
Jul 14, 2001·Journal of the European Academy of Dermatology and Venereology : JEADV·C FerrándizA Smandía
Oct 4, 2005·Arthritis and Rheumatism·Philip J MeaseUNKNOWN Adalimumab Effectiveness in Psoriatic Arthritis Trial Study Group
Mar 17, 2006·Annals of the Rheumatic Diseases·D HuscherUNKNOWN German Collaborative Arthritis Centres
Jul 28, 2006·Arthritis and Rheumatism·William TaylorUNKNOWN CASPAR Study Group
Sep 20, 2006·The Journal of Immunology : Official Journal of the American Association of Immunologists·Eiko ToichiKevin D Cooper
Apr 25, 2007·Scandinavian Journal of Rheumatology·R De AngelisW Grassi
Dec 1, 2007·Arthritis and Rheumatism·Vinod ChandranDafna D Gladman
Jan 22, 2008·Annals of the Rheumatic Diseases·R AxmannG Schett
Feb 15, 2008·International Immunology·Marjaneh RazmaraMark L Tykocinski
Jun 6, 2008·Dermatology : International Journal for Clinical and Investigative Dermatology·I SchaeferM Augustin
Oct 28, 2008·Annals of the Rheumatic Diseases·C T RitchlinUNKNOWN Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA)
Feb 12, 2009·The Journal of Rheumatology·Floranne C WilsonHilal Maradit Kremers
Oct 24, 2009·Clinical Rheumatology·Marwin GutierrezWalter Grassi
Nov 20, 2009·Scandinavian Journal of Rheumatology·Z T LiaoJ R Gu
Apr 8, 2010·Quality of Life Research : an International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation·Andrea Picchianti-DiamantiBruno Laganà
Jan 5, 2011·The Journal of Rheumatology. Supplement·José Alvarez-NemegyeiMaria-Victoria Goycochea-Robles
Feb 4, 2011·Annals of the Rheumatic Diseases·E HaglundM Englund
Sep 29, 2011·Annals of the Rheumatic Diseases·L GossecUNKNOWN European League Against Rheumatism
Oct 4, 2011·Joint, Bone, Spine : Revue Du Rhumatisme·Atsushi OgataToshio Tanaka
Jan 17, 2012·The Journal of Rheumatology·Antonio MarchesoniGabriele DE Marco
Mar 20, 2012·Best Practice & Research. Clinical Rheumatology·Gleison Vieira DuarteJozélio Freire de Carvalho
Jun 13, 2012·Reumatismo·A Spadaro, E Lubrano
Jul 4, 2012·The Journal of Rheumatology. Supplement·Ernesto SosciaRaffaele Scarpa
Jul 4, 2012·The Journal of Rheumatology. Supplement·Alessandro SanduzziRaffaele Scarpa
Jul 24, 2012·Rheumatic Diseases Clinics of North America·Dafna D Gladman

❮ Previous
Next ❯

Citations

Feb 27, 2016·Expert Review of Clinical Pharmacology·Xiaoyu QuYanqing Song
May 11, 2016·Expert Opinion on Biological Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Jun 25, 2017·Advances in Therapy·Yael Renert-Yuval, Emma Guttman-Yassky
Jun 28, 2018·Expert Opinion on Biological Therapy·Ross J ThibodauxLuis R Espinoza
Sep 3, 2017·The Journal of Rheumatology·Raffaele ScarpaIgnazio Olivieri
May 9, 2016·Clinical Rheumatology·Maddalena NapolitanoLuisa Costa
Feb 15, 2020·Expert Opinion on Pharmacotherapy·Francesco CasoLuisa Costa
Mar 21, 2020·Expert Opinion on Emerging Drugs·Esther A BaloghSteven R Feldman
Mar 10, 2020·Expert Review of Clinical Immunology·Francesco CasoLuisa Costa
Sep 12, 2017·Expert Opinion on Pharmacotherapy·Luisa CostaFrancesco Caso
Jul 18, 2018·Clinical Rheumatology·Francesco CasoFabiola Atzeni
Jun 30, 2019·Drugs & Aging·Francesco CasoLuisa Costa
Sep 10, 2020·Biologics : Targets & Therapy·Maria Sole ChimentiRoberto Perricone
Mar 4, 2017·Therapeutic Advances in Musculoskeletal Disease·Michael Reed, David Crosbie
Nov 25, 2020·Rheumatology·Jean-Guillaume LetarouillyRené-Marc Flipo

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2021 Meta ULC. All rights reserved